AAN 2024 Conference
Apr 19, 2024
Unveiling the Promising Long-Term Potential of Subcutaneous Efgartigimod PH20 in Managing gMG
Efgartigimod PH20 is a combination subcutaneous (SC) infusion that contains efgartigimod alfa and hyaluronidase which may be used to improve muscle weakness in adults with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive. The interim results presented by Argenx highlighted notable efficac...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
